Summary Since January 1975 a population-based screening programme for the early detection of breast cancer has been carried out in the city of Nijmegen. During five interscreening periods of 2 years each a total of 158 so-called interval cancers were diagnosed. Careful revision of all screening and diagnostic mammograms was executed. Of all interval cancers 26% were 'missed' at the previous screening examination (due to technical or observer error), 16% were radiographically occult at the time of diagnosis and 58% were 'true' interval cancers. Interval cancers were regarded as 'true' when an obvious lesion was observed on the diagnostic mammogram while no suspect signs were seen on the previous screening mammogram. The prevalence of 'missed' cancers did not decline in the course of the screening programme. Radiographically occult tumours were localised, mostly in Wolfe's P2/DY breast parenchyma (83%), 33% were lobular invasive and 25% ductal non-invasive. 'True' interval cancer cases (58%) showed the same overall survival as control breast cancer patients, diagnosed in a non-screening situation. Shortening the screening interval would reduce interval cancer rates and probably further decrease breast cancer mortality in a screened population. However, from the present series of interval cancers 63% would not have been prevented by an annual screening examination. As regards women under age 50 annual screening would still leave 66% of all interval cancers in this age group undetected. Probably more benefit will be gained by searching for new imaging techniques to reduce numbers of 'missed' cancers and to detect lobular invasive and ductal non-invasive cancers in dense breast parenchyma.
Within any screening programme for the early detection of breast cancer, women are diagnosed as having so-called interval cancer. These cancers surface among negative screenees before the next scheduled examination would have taken place. Of all breast cancers in a screened population about 20-35% are diagnosed within 2 years after the last screening examination (Verbeek, 1985; Tabar et al., 1987; Moskowitz, 1986; de Waard et al., 1984;  Lundgren, 1979) . The survival of patients with interval cancers turned out to be just as bad as the survival of patients diagnosed outside screening programmes (Holmberg et al., 1986; Shapiro et al., 1982) . This finding would seem to suggest that shortening the screening interval to, say, one year might further decrease breast cancer mortality in a population offered a screening programme. The aim of the present study was to search for more evidence validating such recommendations. The issue of screening frequency is especially relevant for women under age 50, since on the one hand no clear-cut evidence of breast cancer mortality reduction has been demonstrated so far in this age group, and on the other hand relatively high interval cancer rates have been observed (Tabar et al., 1987; Moskowitz, 1987) .
Subjects and methods
All data came from the Nijmegen (150,000 inhabitants) screening programme. This population-based project started in January 1975. Single-view mammography was carried out as the only screening examination every two years. In the first screening round (1975/6) women born in the period 1910-39 (n=23,000) were invited. In the subsequent screening rounds women born before 1910 (n=7,700) were invited too; in the fifth screening round the cohort of women born in the period 1940-44 (n=3,900) 
Discussion
The results of our present investigation clearly demonstrate that in this particular two-stage model of hepatocarcinogenesis in rats the supplementation of 0.5 p.p.m. vanadium during the entire experiment, before initiation and during promotion greatly reduced the incidence, multiplicity and size of visible PNs with a concurrent arrest in the number and spread of GGT-positive hepatic foci in total liver parenchyma. In the promotional event, however, these changes did not have any statistical significance. Our data. thus, reveal the unique protective role of vanadium against chemically induced liver tumorigenesis in rats and corroborate our previous findings (Bishayee and Chatterjee. 1995) . This time the anticarcinogenic potential of vanadium is primarily observed on the initiation phase and only secondarily on the promotion stage. In this regard, it is interesting to note that continuous long-term exposure to a low dose of vanadium would elicit a greater protection in terms of the magnitude of preneoplasia than exposure at either the initiation or promotion phase alone. In our experiment. the supplementation of 0.5 p.p.m. vanadium in drinking water, especially during the entire period of the study. resulted in fewer rats developing visible PNs and a smaller number of nodules per nodule-bearing rat liver than those observed in DENA control animals. Another st'king observation of the study was the vanadium-mediated inhibition of the appearance of PNs more than 3 mm in size with a concurrent attenuation of nodular volume as well as nodular volume as a percentage of liver volume. Although it is evident that not all the hepatocyte nodules become cancerous during the lifespan of the animals. numerous observations support the concept that the nodules are the precursors of hepatic cancer (Farber. 1980; Williams. 1980) . Moreover, there is a large body of observational experience in experimental and human disease correlating the number and size of nodular hyperplasia and hepatocarcinoma (Farber and Cameron. 1980: Farber. 1990 ). In view of this. inhibition of nodule growth and enhancement of their regression by vanadium as observed in our study may be important for cancer prevention. especially if one considers that the PNs are easily recognisable and have a low tendency to regress spontaneously. Again, the food and fluid intakes and changes in body weights among different experimental groups were found to be statistically similar. This feature is of paramount importance because nutritional deprivation causing body weight loss may parallel a decrease in tumour volume (Waitzberg et al.. 1989) . Thus. the observed inhibitory effect of vanadium on nodule appearance and its growth is unlikely to be mediated through the impairment of nutritional status in the experimental animals.
It is generally accepted that GGT-positive foci appear to be the first discernible evidence for the occurrence of tumour initiation (Farber. 1980: Pitot and Sirica. 1980) . Moreover. the use of GGT-positive foci in initiation-promotion bioassay is predicted on the assumption that the incidence of foci correlates with the eventual tumour yield that would have occurred had the assav continued until tumour formation (Farber. 1980 : Pereira. 1982 . In the present study. our results clearly showed an inhibitory role of vanadium on the number of GOT-positive preneoplastic focal lesions per cmn of the livers of rats initiated with DENA. As GGT-positive foci represent a transient step to malignancy (Tatematsu et al.. 1988) . the ability of vanadium to reduce the development of GGT-positive foci suggests that this trace element can greatly affect the initiation stages of hepatocarcinogenesis by preventing the initiated cells from growing into preneoplastic foci through an alteration in the efficiency at which DENA can initiate foci appearance. The potential role of vanadium in reducing the number of foci per cmr of liver area was also reflected through a relatively high remodelling and low labelling index. This strongly indicates that a progressive loss of growth capacity by putative preneoplastic cells and their differentiation into normal-appearing hepatocytes proceed to a greater extent in the presence of vanadium.
According to the well-accepted hypothesis of Pitot et al. (1989) . the number and size of altered liver cell foci indicate initiating and promoting activities respectively. In our study. vanadium supplementation not only decreased the number of GGT-positive preneoplastic foci but also caused a decrement in the focal area with a concomitant reduction in focal area as a percentage of liver area, though the results were statistically more significant with respect to focal number. However. this strongly points out the influence of vanadium in inhibiting or slowing the growth of altered liver cell foci. The observed effect of vanadium on focal growth may represent a selective toxicity to proliferating cells by virtue of the fact that they are proliferating compared with a relatively nonproliferating background and thereby eventually suppress the occurrence of hepatocarcinogenesis. In this regard. it is interesting to note that, although GGT-positive foci appeared in the livers of all the vanadium-treated rats concomitant with DENA administration (foci incidence 100%). only a few rats exhibited PNs in their livers (nodule incidence 41.6-72.7% in the three vanadium-supplemented groups). Since PNs arise from enzyme-altered focal growth (Feo et al.. 1988 ). our present findings could be explained in the light of the fact that. although the precursor lesions were still present in the livers of vanadium-exposed rats. their growth rate slowed to such an extent that appearance of PNs was delayed beyond the experimental end point owing to an increased latency penod. This interpretation is supported by our histological assessment, in which the livers of vanadium-supplemented animals (specially in groups C and E) presented a wellmaintained liver architecture with relatively less acidophilic hepatocyte areas than DENA controls.
The enzymatic activity of GGT has been identified as a possible positive marker for preneoplastic hepatocytes (Cameron et al.. 1978: Hanigan and Pitot. 1985 ). In the current study its activity was measured quantitatively in different cell populations during the induction of liver cancer with DENA in the presence or absence of vanadium. Although GGT activity is located inside the plasma membrane, we performed our study using cytosol as it is generally released in a soluble form by homogenisation. Elhkim et al. (1992) also observed that at least 80% of the total GGT activity was present in the cytosolic fraction. Further. PB is known to be a very weak inducer of GOT alone and, in combination with the initiating carcinogen DENA. the induction increases greatly (Shirai et al.. 1985) . The exponential increase in the activity of GGT in PNs and NNSP following DENA injection as observed here resembled a growth process which onrginated as a response to toxic cellular injury. As there is evidence for a close connection between GGT activation and carcinogenesis (Fiala and Fiala. 1973 ). a large increase in this enzyme activity could be correlated with a high nodule incidence, a high total number and a large spread of nodules and foci in hepatic tissue. Vanadiummediated inhibition of GOT-positive hepatocyte foci and PNs during rat liver carcinogenesis initiated with DENA and promoted by PB was well reflected in the relatively low level of this enzymatic activity, which was best observed in the Table IV . 'True' interval cancers did not differ from breast cancers in the control group, they only showed less axillary involvement (35.5% vs. 58.0%, P=0.005). Compared with screen-detected cancers 'true' interval cancers were larger (94% > 10 mm vs. 73%, P= 0.02). Diagnosis was made on average 15.2 months after the previous screening examination. Thirty-six per cent of 'true' interval cancers were diagnosed within one year after the screening examination.
The results of breast cancer screening projects such as the HIP-trial in the United States (Shapiro et al., 1982 ) the DOM-project in Utrecht , the Nijmegen screening project (Verbeek et al., 1984) . the Italian project (Palli et al., 1986) and the Swedish trial (Tabar et al., 1985a) show a considerable reduction of breast cancer mortality. But even though early detection and early treatment are no longer disputed as being beneficial, some unsolved problems remain. One of the major problems one faces in a breast cancer screening project is the number of interval cancers. In the Nijmegen programme, where a screening examination was performed every 2 years, crude interval cancer rates remained relatively stable over the 12-year period. Other studies showed similar interval cancer rates. (Baker, 1982; Frisell et al., 1987; T'abar et al., 1985b) . Interval cancers occurred more frequently among women under 50 years of age, when compared to women aged 50 or older. For younger women the ratio between interval cancers and screen-detected cancers was about 1: 1 while this was about 1:2.5 for women aged 50 or older.
Previous studies (Holland et al., 1982; Newsome & McLelland, 1986; Martin et al., 1979; van Rosen et al., 1985) showed one third of all interval cancers to be missed at a preceding screening examination due to either technical or observer error. In the present study 26% of interval cancers were missed. This percentage did not decline in the course of the programme. To some extent this may have been caused by the entry of new cohorts of women into the screening project. In the Nijmegen programme women born in the period 1940-44 were not invited for a screening examination until 1983/4. Reading mammograms of these young women is difficult due to the high density of the breast parenchyma. Some of the missed cancers, however, were due to nonspecific changes, such as a vague progressive density or a slightly disturbed architectural pattern. Referral of such lesions for further clinical evaluation probably would have resulted in a large number of false-positive screening results. From a total of 153 interval cancers, 16% were radiographically occult at the time of diagnosis. Occult cancers are clinically detectable before they show mammographically suspect signs. During growth they tend to remain obscured by dense P2/DY breast parenchyma. Occult cancers often were of lobular invasive or ductal non-invasive histological type. In other studies about 5-7% of breast cancer patients were reported to have negative mammograms. Patients were younger compared with all other breast cancer patients (Burns et al., 1979; Cahill et al., 1981) . Here the limits of modern mammography have been reached since in dense breast parenchyma these types of breast cancers probably cannot be visualised (Holland et al., 1983) .
Of all interval cancers 58% showed no suspect lesions on a previous screening mammogram, while they were visible at the time of diagnosis. They were either masked in some way at the previous examination or were newly grown, which implies a high growth rate. A similar percentage of 'true' interval cancers (52%) was found in the Stockholm screening programme (Frisell et al., 1987) . Although in patients with 'true' interval cancers axillary lymph node involvement was statistically significantly less frequent (36% vs. 58%) when compared with control breast cancer patients, 7-year overall survival was equal. These results are identical to those reported by others (Holmberg et al., 1986; Shapiro et al., 1982) . It is often argued that shortening the screening interval would reduce the number of interval cancers (Tab'ar et al., 1987; Moskowitz & Gartside, 1982) . Especially the high proportion of interval cancers occurring in women under age 50 is reported to cause the absence of a clear reduction in mortality in women from this age-group, after participating in a screening programme. More frequent screening will probably not affect the number of 'missed' cancers, since the same error rates of about 30% are found in studies with different screening intervals (Baker, 1982; Holland et al., 1982; Newsome & McLelland, 1986; Martin et al., 1979) . In the Nijmegen project the prevalence of 'missed' interval cancers did not decrease during the progress of the programme. More frequent screening will certainly not improve the detection of radiographically occult breast cancers, it can only influence the 'true' interval cancer group of 58%. However, since 32 of these 89 interval cancers occurred within one year after the previous screening examination an annual screening examination would still leave 40 ('missed' cancers) plus 24 (radiographically occult cancers) plus 32 ('true' interval cancers occurring within one year) undetected. So from the present series of 153 interval cancers, 96 (63%) would not have been prevented by more frequent screening. As regards women under age 50, from a total of 51 interval cancers (50, one missing) 11 were 'missed' at the previous screening examination, 12 were radiographically occult and 10 of the 'true' interval cancers occurred within one year after the preceding screening examination. For this agegroup shortening the screening interval from 2 years to 1 year would prevent 34% of interval cancers. This age-group would probably benefit more from the development of new imaging techniques to detect specific lobular invasive and ductal non-invasive cancers in dense breast tissue.
